Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome

Neurology

Volumn 53, Issue 2, 1999, Pages 371-374

  Meyer, P ^a   Bohnen, N I ^a   Minoshima, S ^a   Koeppe, R A ^a   Wernette, K ^a   Kilbourn, M R ^a   Kuhl, D E ^a   Frey, K A ^a   Albin, Roger L ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Neuroscience Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BINDING SITE; CLINICAL ARTICLE; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; GILLES DE LA TOURETTE SYNDROME; HUMAN; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION;

EID: 0033595182     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.2.371     Document Type: Article

References (28)

1. Robertson MM, Stern JS. The Gilles de la Tourette syndrome. Crit Rev Neurobiol 1997;11:1-19.
2. Robertson MM. D2 be or not to be? Nat Med 1996;2: 1076-1077.
3. Devinsky O. Neuroanatomy of Gilles de la Tourette's syndrome: possible midbrain involvement. Arch Neurol 1983;40: 508-514.
4. Singer HS, Butler IJ, Tune LE, Seifert WE, Coyle JT. Dopaminergic dysfunction in Tourette syndrome. Ann Neurol 1982;12: 361-366.
5. Brooks DJ, Turjanski N, Sawle GV, Playford ED, Lees AJ. PET studies on the integrity of the pre and postsynaptic dopaminergic system in Tourette syndrome. Adv Neurol 1992;58: 227-231.
6. George MS, Robertson MM, Costa DC, et al. Dopamine receptor availability in Tourette's syndrome. Psychiatry Res 1994; 55:193-203.
7. Turjanski N, Sawle GV, Playford ED, et al. PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. J Neurol Neurosurg Psychiatry 1994;57: 688-692.
8. Wong DF, Singer HS, Brandt J, et al. D2 like dopamine receptor density in Tourette syndrome measured by PET. J Nucl Med 1997;38:1243-1247.
9. Wolf SS, Jones DW, Knable MB, et al. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science 1996;273: 1225-1227.
10. 123I]-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 1995;152:1359-1361.
11. Singer HS, Hahn IH, Moran TH. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Ann Neurol 1991;30:558-562.
12. Vander Borght TM, Kilbourn MR, Koeppe RA, et al. In vivo imaging of the brain vesicular monoamine transporter. J Nucl Med 1995;36:2252-2260.
13. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995;294: 577-583.
14. Kilbourn MR, Frey KA, Vander Borght T, Sherman PS. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain monoamine transporters. Nucl Med Biol 1996;23:467-471.
15. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996;40:873-884.
16. 3H]Methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 1995;68:955-962.
17. Naudon L, Leroux-Nicollet I, Costentin J. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter. Neurosci Lett 1994;173:1-4.
18. Goetz CG, et al. A rating scale for Gilles de la Tourette's syndrome: description, reliability, and validity data. Neurology 1987;37:1542-1544.
19. 11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab 1997;17:919-931.
20. 11C]dihydrotetrabenazine (DTBZ). Nucl Med Biol 1997;24: 197-199
21. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 1991;11:735-744.
22. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984;15:217-227.
23. 11]WIN35,428 are elevated in Tourette syndrome patients. J Nucl Med 1994;40:130P. Abstract.
24. Szymanski S, Singer H, Ginliano J, et al. Increased intrasynaptic dopamine release in Tourette syndrome. J Cereb Blood Flow Metab 1997;17:S732. Abstract.
25. Singer HS. Neurobiology of Tourette syndrome. Neurol Clin 1997;15:357-379.
26. Heinz A, Knable MB, Wolf SS, et al. Tourette's syndrome: [I-123]β-CIT SPECT correlates of vocal tic severity. Neurology 1998;51:1069-1074.
27. 3H]Dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J Neurochem 1988;50:1131-1136.
28. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996;47: 718-726.